SCHEMBL738495

SCHEMBL738495

c1ccc(C(c2ccccc2)n2ccnc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 12/20 1.00
CYP17A1 P05093 2/20 0.83
MEN1 O00255 1/20 0.83
NR1I2 O75469 1/20 0.83
USP2 O75604 1/20 0.83
ABCB11 O95342 1/20 0.83
ALDH1A1 P00352 1/20 0.83
PLA2G1B P04054 1/20 0.83
TP53 P04637 1/20 0.83
PGR P06401 1/20 0.83
HSP90AA1 P07900 1/20 0.83
CYP3A4 P08684 1/20 0.83
MAPT P10636 1/20 0.83
IDO1 P14902 1/20 0.83
HPGD P15428 1/20 0.83
MAOA P21397 1/20 0.83
CNR1 P21554 1/20 0.83
HTR2A P28223 1/20 0.83
MAPK1 P28482 1/20 0.83
ADRA1A P35348 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28169692 0.98 CYP19A1 (0.96) CYP19A1CYP17A1MEN1NR1I2USP2
Bromide SCHEMBL28170216 0.98 CYP19A1 (0.96) CYP19A1CYP17A1MEN1NR1I2USP2
Bifonazole SCHEMBL1606037 0.91 CYP17A1 (1.00) CYP19A1CYP17A1MEN1NR1I2USP2
Bifonazole SCHEMBL36803 0.91 CYP17A1 (1.00) CYP19A1CYP17A1MEN1NR1I2USP2
Bifonazole SCHEMBL1551534 0.91 CYP17A1 (1.00) CYP19A1CYP17A1MEN1NR1I2USP2
Bifonazole SCHEMBL7598897 0.91 CYP17A1 (1.00) CYP19A1CYP17A1MEN1NR1I2USP2
Bifonazole SCHEMBL394764 0.91 CYP17A1 (1.00) CYP19A1CYP17A1MEN1NR1I2USP2
SCHEMBL667347 0.89 CYP19A1 (0.80) CYP19A1CYP17A1MEN1NR1I2USP2
SCHEMBL11366789 0.89 CYP19A1 (1.00) CYP19A1CYP17A1MEN1NR1I2USP2
SCHEMBL11349905 0.89 CYP17A1 (1.00) CYP19A1CYP17A1MEN1NR1I2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108690217-B Carbon fiber recycling composition and method 波音公司 2022-07-15 CN claimed
CN-114479795-A Expanded particle composite water shutoff agent, preparation method thereof and water shutoff construction method 中国石油化工股份有限公司 2022-05-13 CN claimed
CN-110003869-B Crack plugging agent based on expanded particles and curable particles 西南石油大学 2021-04-06 CN claimed
CN-107365439-B Novel chloroprene rubber vulcanization method 华南理工大学 2020-02-18 CN claimed
US-10125226-B2 Scale-up process of bifunctionalized triblock copolymers with secondary and tertiary amines, with application in dewatering and desalting of heavy crude oils INSTITUTO MEXICANO DEL PETROLEO (MX) 2018-11-13 US claimed
US-20140364566-A1 SCALE-UP PROCESS OF BIFUNCTIONALIZED TRIBLOCK COPOLYMERS WITH SECONDARY AND TERTIARY AMINES, WITH APPLICATION IN DEWATERING AND DESALTING OF HEAVY CRUDE OILS INSTITUTO MEXICANO DEL PETROLEO (MX) 2014-12-11 US claimed
JP-62205002-A None JP disclosed
JP-5078328-A None JP disclosed
US-20250340591-A1 COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND ANYGEN CO LTD (KR) 2025-11-06 US disclosed
WO-2024261723-A1 RHENIUM COMPLEXES COMPRISING A LIGAND WITH A DISTAL INVERTED TRIGONAL PYRAMIDAL STRUCTURAL MOTIF AND USE THEROF UNIVERSIDADE NOVA DE LISBOA (PT) 2024-12-26 WO disclosed
CN-117542473-A Method for treating hypertension with pharmaceutical compositions of angiotensin II receptor blockers 阿斯利康(英国)有限公司 2024-02-09 CN disclosed
US-20240006084-A1 METHODS FOR TREATMENT OF HYPERTENSION WITH AN ANGIOTENSIN II RECEPTOR BLOCKER PHARMACEUTICAL COMPOSITION ASTRAZENECA UK LIMITED (GB) 2024-01-04 US disclosed
CN-112567469-B Method for treating hypertension with pharmaceutical compositions of angiotensin II receptor blockers 阿斯利康(英国)有限公司 2023-11-07 CN disclosed
EP-0281121-A1 1-(1-Aryl-2-hydroxy-ethyl)-imidazoles and their salts, processes for their preparation, drugs containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1988-09-07 EP disclosed
JP-S62205002-A PLANT GROWTH REGULATOR HODOGAYA CHEM CO LTD 1987-09-09 JP disclosed
EP-0000373-B1 IMIDAZOLE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PLANT GROWTH REGULANTS OR PLANT PROTECTION AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1981-01-07 EP disclosed
US-4182624-A FUNGICIDES, HERBICIDES, PLANT GROWTH REGULATORS HOECHST AKTIENGESELLSCHAFT (DE) 1980-01-08 US disclosed
US-4182624-A FUNGICIDES, HERBICIDES, PLANT GROWTH REGULATORS HOECHST AKTIENGESELLSCHAFT (DE) 1980-01-08 US disclosed
EP-0003796-A1 Substituted diphenylmethyl-imidazoles, their preparation and medicaments containing them BAYER AG (DE) 1979-09-05 EP disclosed
EP-0000373-A1 Imidazole carboxylic acids and derivatives thereof, process for their preparation and their use as plant growth regulants or plant protection agents HOECHST AKTIENGESELLSCHAFT (DE) 1979-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240006084-A1 METHODS FOR TREATMENT OF HYPERTENSION WITH AN ANGIOTENSIN II RECEPTOR BLOCKER PHARMACEUTICAL COMPOSITION AGTR2, AGTR1, REN CYP19A1 3045/4885CYP17A1 1688/4885MEN1 4312/4885
US-20250340591-A1 COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND GPR39, FABP2, GPR119 CYP19A1 2731/4885CYP17A1 1758/4885MEN1 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.